B
17.29
-0.12 (-0.69%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Bicara Therapeutics Inc. | - | - |
AIStockmoo Score
1.0
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.26% |
| % Held by Institutions | 67.15% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Omega Fund Management, Llc | 30 Sep 2024 | 2,204,650 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 47.00 (Stifel, 171.83%) | Buy |
| Median | 42.00 (142.92%) | |
| Low | 35.00 (Morgan Stanley, 102.43%) | Buy |
| Average | 41.33 (139.04%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 22.07 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 06 Dec 2024 | 42.00 (142.91%) | Buy | 21.10 |
| Morgan Stanley | 08 Oct 2024 | 35.00 (102.43%) | Buy | 22.55 |
| Stifel | 08 Oct 2024 | 47.00 (171.83%) | Buy | 22.55 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |